stalled for 9 weeks at 12.5mg and I refuse to panic this time
Genuinely asking, not being difficult.
Everyone in c/tirzepatide repeats that biopsy is important. I believe it, but I have never seen anyone show why, and when I search I get 17 threads of people agreeing with each other.
Is there a paper? Is there a measurement? Or is this one of those things that is true because it has been repeated since 2023?
I am not trying to be the "source?" guy. I would just like a source.
best — the order this archive was captured in
My version of this: I was so worried about the injection that I put it off for eleven days. The injection is the easiest part.
Disagree. What you are describing is consistent with biopsy, not with what you concluded.
[removed by moderator]
[removed by moderator]
Disagree on that part. 98.7% and 98.3% on the same vial is normal.
Edit to your parent would help — the concentration you quoted assumes one scenario and you have written another above it.
not approved, descriptive posts only
Hepatic fat or MASH or what?
phase 11 data is interesting, phase 26 will be different
Phase 5 or 28?
MASH claims need the trial and the biopsy endpoint
Tracking number removed. It identifies both ends of a shipment.
This is correct. Do not generalise from tirzepatide.
Disagree. What you are describing is consistent with dual agonist, not with what you concluded.
the GLP-1/glucagon dual is glucagon, different from GIP/GLP-1
phase 14 data is interesting, phase 35 will be different
MASH claims need the trial and the biopsy endpoint
Dead space in the needle hub holds a small but non-trivial volume. On low-volume draws that can be several units.
hepatic fat and MASH are the story
- 1Disagree. What you are describing is consistent with biopsy, not with what…6 comments in this branch · started by u/nora_oyelaran
- 2This is correct. Do not generalise from tirzepatide.6 comments in this branch · started by u/chidi_demir